Literature DB >> 16304574

Acute myelogenous leukemia in Chile PINDA protocols 87 and 92 results.

J Quintana, P Advis, A Becker, V Beresi, M Campbell, E F Vinés, H García, C Salgado, L Vargas, J Rojas, M Obando, L Neira, E Páez, P Zolezzi.   

Abstract

Entities:  

Mesh：

Year:  2005        PMID： 16304574     DOI： 10.1038/sj.leu.2403959

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  10 in total

Review 1.  Biology, risk stratification, and therapy of pediatric acute leukemias: an update.

Authors:  Ching-Hon Pui; William L Carroll; Soheil Meshinchi; Robert J Arceci
Journal:  J Clin Oncol       Date:  2011-01-10       Impact factor: 44.544

Review 2.  Global characteristics of childhood acute promyelocytic leukemia.

Authors:  L Zhang; A Samad; M S Pombo-de-Oliveira; G Scelo; M T Smith; J Feusner; J L Wiemels; C Metayer
Journal:  Blood Rev       Date:  2014-09-30       Impact factor: 8.250

3.  Survival of Mexican children with acute myeloid leukaemia who received early intensification chemotherapy and an autologous transplant.

Authors:  Elva Jiménez-Hernández; María Teresa Dueñas-González; José Arellano-Galindo; María Elena Medrano-Ortíz-De-Zárate; Vilma Carolina Bekker-Méndez; Adolfina Berges-García; Karina Solís-Labastida; Berenice Sánchez-Jara; Héctor Manuel Tiznado-García; Ethel Zulie Jaimes-Reyes; Xochiketzalli García-Jiménez; Laura Espinoza-Hernández; Nora Nancy Núñez-Villegas; Sergio Franco-Ornelas; Ruy Xavier Pérez-Casillas; Octavio Martínez Villegas; Teresa Marin Palomares; Juan Manuel Mejía-Aranguré
Journal:  Biomed Res Int       Date:  2015-03-02       Impact factor: 3.411

4.  LncRNA ANRIL regulates AML development through modulating the glucose metabolism pathway of AdipoR1/AMPK/SIRT1.

Authors:  Lin-Yu Sun; Xiao-Juan Li; Yu-Meng Sun; Wei Huang; Ke Fang; Cai Han; Zhen-Hua Chen; Xue-Qun Luo; Yue-Qin Chen; Wen-Tao Wang
Journal:  Mol Cancer       Date:  2018-08-22       Impact factor: 27.401

5.  Long noncoding RNA HOXA-AS2 functions as an oncogene by binding to EZH2 and suppressing LATS2 in acute myeloid leukemia (AML).

Authors:  Yubin Feng; Shuang Hu; Lanlan Li; Xiaoqing Peng; Feihu Chen
Journal:  Cell Death Dis       Date:  2020-12-02       Impact factor: 8.469

6.  Evaluation of the Pediatric Neuro-Oncology Resources Available in Chile.

Authors:  Mohammad H Abu-Arja; Nicolás Rojas Del Río; Andres Morales La Madrid; Alvaro Lassaletta; Scott L Coven; Rosa Moreno; Miguel Valero; Veronica Perez; Felipe Espinoza; Eduardo Fernandez; José Santander; Juan Tordecilla; Veronica Oyarce; Katherine Kopp; Ute Bartels; Ibrahim Qaddoumi; Jonathan L Finlay; Adrián Cáceres; Mauricio Reyes; Ximena Espinoza; Diana S Osorio
Journal:  JCO Glob Oncol       Date:  2021-03

7.  A novel upregulated LncRNA-AC026150.8 promotes chemo-resistance and predicts poor prognosis in acute myeloid leukemia.

Authors:  Henan Zhang; Yue Zhao; Xuan Liu; Yusi Liu; Xiaohui Wang; Yu Fu; Shuang Fu; Jihong Zhang
Journal:  Cancer Med       Date:  2021-10-19       Impact factor: 4.452

Review 8.  Mapping Pediatric Oncology Clinical Trial Collaborative Groups on the Global Stage.

Authors:  Ajay Major; Monica Palese; Ebru Ermis; Anthony James; Milena Villarroel; Federico Antillon Klussmann; Laila Hessissen; Jennifer Geel; Muhammad Saghir Khan; Rashmi Dalvi; Michael Sullivan; Pamela Kearns; A Lindsay Frazier; Kathy Pritchard-Jones; Akira Nakagawara; Carlos Rodriguez-Galindo; Samuel L Volchenboum
Journal:  JCO Glob Oncol       Date:  2022-02

9.  Outcomes of pediatric acute myeloid leukemia treatment in Western Kenya.

Authors:  Romy E van Weelderen; Festus Njuguna; Kim Klein; Saskia Mostert; Sandra Langat; Terry A Vik; Gilbert Olbara; Martha Kipng'etich; Gertjan J L Kaspers
Journal:  Cancer Rep (Hoboken)       Date:  2021-11-22

10.  E2F4 functions as a tumour suppressor in acute myeloid leukaemia via inhibition of the MAPK signalling pathway by binding to EZH2.

Authors:  Yubin Feng; Lanlan Li; Yan Du; Xiaoqing Peng; Feihu Chen
Journal:  J Cell Mol Med       Date:  2020-01-14       Impact factor: 5.310
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.